Loading
Latest filing published 30 Nov 2022 for Navidea Biopharmaceuticals, INC..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Malcolm G. Witter (board member) discloses dealings in Navidea Biopharmaceuticals, Inc. to SEC (Form 4). Between 28 December 2020 and 30 November 2022, the trades on record add up to 25 filings.
The open-market record is one-sided, with 6 purchases worth €137k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 19 share grants.
A typical purchase (the median) is worth €24k. No cluster: in 6 purchases, no other insider of the company bought within 30 days.
The latest filing, published on 30 November 2022, reports a share grant in Navidea Biopharmaceuticals, Inc. The last purchase on record was published on 17 September 2021, which is 1,863 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations